INNATE PHARMA SA (IPH.PA)

FR0010331421 - Common Stock

2.12  -0.03 (-1.4%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
12.112M
-78.43%		49.58M
309.35%		51.901M
4.68%		35.662M
-31.29%
EBITDA
YoY % growth
-43.229M
-174.69%		28.98M
167.04%		-7.578M
-126.15%		-47.538M
-527.32%		N/AN/AN/A
EBIT
YoY % growth
-47.825M
-4,532.34%		-16.425M
65.66%		-12.669M
22.87%		-48.657M
-284.07%
Operating Margin
-394.86%-33.13%-24.41%-136.44%
EPS
YoY % growth
N/AN/AN/A-0.38N/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q2 2019
Q2Q % growth		 0.20 0.32-0.12-38.12%
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q4 2020
Q2Q % growth		 26.31M
51.33%		27.379M-1.069M-3.90%
Q4 2019
Q2Q % growth		 17.386M
-72.41%		22.285M-4.899M-21.98%
Q2 2019
Q2Q % growth		 51.588M
218.25%		58.735M-7.147M-12.17%
Q4 2018
Q2Q % growth		 63.01M
268.91%		38.929M24.081M61.86%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 27.88% 40.44%
RevenueN/A N/A -13.43% -14.82%